AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Biodexa on 3/19 was $103.55 Million, Ranking 786
ByAinvest
Wednesday, Mar 19, 2025 6:20 pm ET1min read
The turnover of Biodexa on 3/19/2025 was $103.55 million, ranking 786 in today's market, the Volume is 38.34 million.
Biodexa(BDRX) shares closed at $2.34, up 16.13% on 3/19/2025, up 19.39% in the last 5 trading days, down 29.73% this month, down 42.22% year-to-date and down 91.09% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 3/19/2025 | $103.55 million | 38.34 million | $2.34 | 16.13% |
| 3/18/2025 | $0.13 million | 0.06 million | $2.015 | -4.95% |
| 3/17/2025 | $0.20 million | 0.10 million | $2.12 | 11.58% |
| 3/14/2025 | $0.19 million | 0.10 million | $1.9 | -4.52% |
| 3/13/2025 | $0.32 million | 0.16 million | $1.99 | 1.53% |
【Company Profile】
Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales, referred to as Midatech, is a specialty pharmaceutical company focused on the development and commercialization of multiple therapeutic products, using its nanomedicine and sustained release technologies, to enhance the delivery of medicines in major diseases with unmet medical need. These diseases include diabetes, certain cancers such as liver, pancreatic, ovarian and brain (glioblastoma), and neurological/ophthalmologic conditions. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet